J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals
Source: BioPharma Dive - Latest News
J&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s top venture rounds.